drugset / Trial / NCT01711242
Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
RandomizedParallel-groupSingle-blindTreatment
Summary
The objective of the trial is to compare disease-free survival between adjuvant XELOX alone vs XELOX with concurrent capecitabine and radiotherapy in curatively resected gastric cancer patients with D2 dissection.
Timeline
- Start
- 2012-01
- Primary completion
- 2020-01
- Completion
- 2021-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |